Bayan Health review

Bayan Health facilitates telehealth services rather than itself prescribing medication. Its FAQ identifies MDIntegrations as a clinical network and describes assessment by video, audio or secure messaging, with testing when needed. The same FAQ advertises nationwide access but qualifies it by clinician authorization, individual treatment eligibility, state rules and pharmacy availability. This is not a guarantee that every product can be prescribed at every address. Ask for the actual treating professional, the proposed formulation and the dispensing pharmacy. A general description of a network is different from verifying the individual clinician and facility assigned to a particular order.

The active catalog includes BPC-157 and several other investigational peptide listings alongside GLP-1, hormone and longevity care. The BPC-157 page combines claims about tissue repair and inflammation with an acknowledgment that human research is limited and the product is not FDA-approved. A medical review and a compounded-drug disclaimer do not establish that a preparation satisfies the applicable federal conditions or is being provided under authorized research. Ingredient and formulation differences matter. Bayan remains outside the recommendations because its reviewed catalog disclosures do not establish an appropriate routine pathway for these offerings, rather than because every medicine on the site shares one legal status.

The semaglutide page describes a bundled monthly price including medication, consultation and expedited shipping, with no separate membership fee and the same price across its listed doses. It also requires an initial three-month protocol, shipped together if approved, while payments are collected monthly. The sermorelin page describes a similar initial commitment. A monthly installment is therefore not necessarily a plan that can be stopped after a single month without remaining payments. The terms expressly say the payment obligation covers the entire dispensed protocol. Confirm the complete commitment total, product-specific dates and later renewal terms before authorizing the first payment.

NAD+ injections follow a different schedule. The current product page expressly says billing occurs every twenty-five days, while each shipment contains ten weeks of medication and an initial ten-week commitment applies. Its frequently asked questions also use ongoing-until-canceled language, so obtain written confirmation of the earliest cancellation date. A twenty-five-day charge must not be labeled a calendar-month payment or inferred from the shipment duration. Normalized comparison prices remain unquoted until the selected agreement and complete obligation are clear. Neither NAD+’s cellular role nor a bundled consultation establishes that the injections improve energy, cognition or healthy aging in an individual patient.

Renewal and cancellation require advance attention. The terms require opting out at least fifteen days before the next recurring protocol cycle, potentially triggering another sixty- or ninety-day commitment if that window is missed. Some product pages instead say cancellation before the next billing date after the initial commitment. Resolve that timing difference in writing rather than assuming the shorter window controls. The FAQ’s general flexible-plan language also does not override a product’s stated initial commitment. Keep the selected agreement and cancellation acknowledgment, especially where multiple monthly installments pay for medication delivered together rather than separate monthly shipments.

The current terms say consultation fees are generally non-refundable once clinical review begins, and medication may become non-refundable when prescribed, processed, compounded, dispensed, shipped or otherwise prepared. This is more specific than a blanket assertion that every sale is final or that all fees must remain payable after any clinical refusal. Incomplete, incorrect or damaged shipments generally require written notice within twenty-four hours of delivery, with stated exceptions for documented carrier problems or circumstances beyond reasonable control. The FAQ describes pharmacy partners without naming the actual facility; verify that identity separately. Expedited shipping remains subject to approval, pharmacy processing and carrier conditions.